Theravance Biopharma

Ownership
-
Employees
99
Market Cap
-
Website
Introduction

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded i...

Clinical Trials
Related News

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

First Posted Date
2016-01-15
Last Posted Date
2021-01-19
Lead Sponsor
Theravance Biopharma
Target Recruit Count
72
Registration Number
NCT02657122
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo Comparator
Drug: TD-0714
First Posted Date
2015-12-24
Last Posted Date
2021-10-13
Lead Sponsor
Theravance Biopharma
Target Recruit Count
56
Registration Number
NCT02639078
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Phase 2
Completed
Conditions
Gastroparesis
Interventions
Drug: Placebo
Drug: Velusetrag
First Posted Date
2014-10-17
Last Posted Date
2018-04-17
Lead Sponsor
Theravance Biopharma
Target Recruit Count
233
Registration Number
NCT02267525

TD-6450 MAD Study in HCV Infected Subjects

Phase 1
Completed
Conditions
HCV
Hepatitis C
Interventions
Drug: Placebo
Drug: TD-6450
First Posted Date
2014-04-17
Last Posted Date
2021-01-19
Lead Sponsor
Theravance Biopharma
Target Recruit Count
47
Registration Number
NCT02116543
Locations
🇺🇸

Texas Liver Institute, San Antonio, Texas, United States

TD-6450 SAD and MAD in Healthy Subjects

Phase 1
Completed
Conditions
Hepatitis C
Interventions
Drug: TD-6450
Drug: Placebo
First Posted Date
2013-12-27
Last Posted Date
2021-01-14
Lead Sponsor
Theravance Biopharma
Target Recruit Count
111
Registration Number
NCT02022306
Locations
🇺🇸

ICON Development Solutions, San Antonio, Texas, United States

TD-1607 MAD Study in Healthy Subjects

Phase 1
Completed
Conditions
Bacterial Infections
Infections
Interventions
Drug: TD-1607
Drug: Placebo
First Posted Date
2013-09-24
Last Posted Date
2021-01-19
Lead Sponsor
Theravance Biopharma
Target Recruit Count
48
Registration Number
NCT01949103
Locations
🇺🇸

PPD, Phase 1 Clinic, Austin, Texas, United States

TD-9855 Mass Balance Study

Phase 1
Completed
Conditions
ADHD
Fibromyalgia
Interventions
Drug: TD-9855
First Posted Date
2013-08-16
Last Posted Date
2021-01-19
Lead Sponsor
Theravance Biopharma
Target Recruit Count
6
Registration Number
NCT01924143

TD-1607 SAD Study in Healthy Subjects

First Posted Date
2013-02-13
Last Posted Date
2021-01-19
Lead Sponsor
Theravance Biopharma
Target Recruit Count
64
Registration Number
NCT01791049
Locations
🇺🇸

PPD Phase 1, Austin, Texas, United States

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

First Posted Date
2012-11-01
Last Posted Date
2018-02-26
Lead Sponsor
Theravance Biopharma
Target Recruit Count
34
Registration Number
NCT01718938
Locations
🇺🇸

Wake Research Associates, LLC, Raleigh, North Carolina, United States

🇺🇸

Axis Clinical Trials, Los Angeles, California, United States

🇺🇸

GI Associates & Endoscopy Center, Jackson, Mississippi, United States

and more 6 locations

TD-1211 IV/Oral Mass Balance Study

Phase 1
Completed
Conditions
OIC
Interventions
Drug: TD-1211 IV [C14]
Drug: TD-1211 PO [C14]
First Posted Date
2012-10-05
Last Posted Date
2021-01-20
Lead Sponsor
Theravance Biopharma
Target Recruit Count
10
Registration Number
NCT01702194
Locations
🇺🇸

Covance, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy